Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.
Posttranslational proteolytic processing of chemokines is a natural mechanism to regulate inflammation. In this study, we describe modification of the CXC chemokine stromal cell-derived factor 1alpha/CXCL12 by peptidylarginine deiminase (PAD) that converts arginine residues into citrulline (Cit), thereby reducing the number of positive charges. The three NH(2)-terminal arginines of CXCL12, Arg(8), Arg(12), and Arg(20), were citrullinated upon incubation with PAD. The physiologic relevance of citrullination was demonstrated by showing coexpression of CXCL12 and PAD in Crohn's disease. Three CXCL12 isoforms were synthesized for biologic characterization: CXCL12-1Cit, CXCL12-3Cit, and CXCL12-5Cit, in which Arg(8), Arg(8)/Arg(12)/Arg(20), or all five arginines were citrullinated, respectively. Replacement of only Arg(8) caused already impaired (30-fold reduction) CXCR4 binding and signaling (calcium mobilization, phosphorylation of ERK and protein kinase B) properties. Interaction with CXCR4 was completely abolished for CXCL12-3Cit and CXCL12-5Cit. However, the CXCR7-binding capacities of CXCL12-1Cit and CXCL12-3Cit were, respectively, intact and reduced, whereas CXCL12-5Cit failed to bind CXCR7. In chemotaxis assays with lymphocytes and monocytes, CXCL12-3Cit and CXCL12-5Cit were completely devoid of activity, whereas CXCL12-1Cit, albeit at higher concentrations than CXCL12, induced migration. The antiviral potency of CXCL12-1Cit was reduced compared with CXCL12 and CXCL12-3Cit and CXCL12-5Cit (maximal dose 200 nM) could not inhibit infection of lymphocytic MT-4 cells with the HIV-1 strains NL4.3 and HE. In conclusion, modification of CXCL12 by one Cit severely impaired the CXCR4-mediated biologic effects of this chemokine and maximally citrullinated CXCL12 was inactive. Therefore, PAD is a potent physiologic down-regulator of CXCL12 function.
Struyf
Sofie
S
Rega Institute for Medical Research, Laboratory of Molecular Immunology, University of Leuven, Leuven, Belgium.
Noppen
Samuel
S
Loos
Tamara
T
Mortier
Anneleen
A
Gouwy
Mieke
M
Verbeke
Hannelien
H
Huskens
Dana
D
Luangsay
Souphalone
S
Parmentier
Marc
M
Geboes
Karel
K
Schols
Dominique
D
Van Damme
Jo
J
Proost
Paul
P
D000818:Animals; D019380:Anti-HIV Agents / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D016466:CHO Cells; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D054377:Chemokine CXCL12 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D002956:Citrulline / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D003424:Crohn Disease / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006867:Hydrolases / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology; D011485:Protein Binding / Q000276:immunology; D000076342:Protein-Arginine Deiminases; D054387:Receptors, CXCR / Q000037:antagonists & inhibitors* / Q000378:metabolism* / Q000502:physiology; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000378:metabolism* / Q000502:physiology
C501896:ACKR3 protein, human; D019380:Anti-HIV Agents; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D018836:Inflammation Mediators; D054387:Receptors, CXCR; D019718:Receptors, CXCR4; D002956:Citrulline; D006867:Hydrolases; D000076342:Protein-Arginine Deiminases